Download PDF
J Knee Surg 2019; 32(10): 995-1000
DOI: 10.1055/s-0038-1675217
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

A Retrospective Comparative Study of Different Methods of Blood Management in Total Knee Replacement

Eleni Pappa
1   1st Department of Orthopaedics, ‘Hygeia’ General Hospital of Athens, Marousi, Greece
,
Nikolaos Vergados
1   1st Department of Orthopaedics, ‘Hygeia’ General Hospital of Athens, Marousi, Greece
,
Emanouil Spiridakis
1   1st Department of Orthopaedics, ‘Hygeia’ General Hospital of Athens, Marousi, Greece
,
George Chountas
1   1st Department of Orthopaedics, ‘Hygeia’ General Hospital of Athens, Marousi, Greece
,
Anna Apostolopoulou
1   1st Department of Orthopaedics, ‘Hygeia’ General Hospital of Athens, Marousi, Greece
,
Savas Sourmelis
1   1st Department of Orthopaedics, ‘Hygeia’ General Hospital of Athens, Marousi, Greece
› Author Affiliations
Further Information

Publication History

18 December 2017

07 September 2018

Publication Date:
13 November 2018 (online)

    Permissions and Reprints

Abstract

Perioperative blood management is essential to minimize allogeneic blood transfusion in total knee replacement. The effect of preoperative administration of erythropoietin, intraoperative cell saver, tranexamic acid, and restrictive transfusion strategies on allogeneic transfusion is studied in total knee replacement. A retrospective comparative study of 106 patients who underwent total knee replacement in different time periods was performed. Group A (n 1 = 45) underwent restrictive strategies of transfusion between 2009 and 2010. Group B (n 2 = 24) includes patients where erythropoietin of either 10.000 IU or 20.000 IU was given preoperatively. Patients of Group C (n 3 = 21) underwent autologous washed erythrocytes transfusion through a cell saver. Lastly, in Group D (n 4 = 15) tranexamic acid dose of 1 gr IV was given intraoperatively. The preoperative and discharge hemoglobin together with total units of blood transfusion and creatinine levels was studied. Tranexamic acid noted the least units of blood transfusion (mean = 0.82 units/patient, p < 0.001, CI 95%) in contrast to the two regimens of erythropoietin (1.16 units/patient) OrthoPAT (1.43 units/patient) and restrictive strategies (1.92 units/patient). The mean preoperative hemoglobin was 13.37 g/dL with no statistical difference among the groups of patients. The postoperative mean hemoglobin was 10.59 with no statistical difference among the groups of patients too. Additionally, the mean creatinine level was 0.93 mg/dL; however, no statistical difference among the groups of patients was noted. Finally, tranexamic acid seemed to be the most cost-effective regime. In our study, tranexamic acid proved its superiority concerning the postoperative blood transfusion on patients undergoing total knee replacement, in comparison with the other existing methods of perioperative blood management. This is a Level III, retrospective comparative study.

Keywords

blood management - total knee replacement - tranexamic acid
 

  • References

  • 1 Toy PT, Kaplan EB, McVay PA, Lee SJ, Strauss RG, Stehling LC. ; The Preoperative Autologous Blood Donation Study Group. Blood loss and replacement in total hip arthroplasty: a multicenter study. Transfusion 1992; 32 (01) 63-67
    CrossrefPubMedGoogle Scholar
  • 2 Frisch NB, Wessell NM, Charters MA, Yu S, Jeffries JJ, Silverton CD. Predictors and complications of blood transfusion in total hip and knee arthroplasty. J Arthroplasty 2014; 29 (9, Suppl): 189-192
    CrossrefPubMedGoogle Scholar
  • 3 Keating EM, Meding JB, Faris PM, Ritter MA. Predictors of transfusion risk in elective knee surgery. Clin Orthop Relat Res 1998; (357) 50-59
    PubMedGoogle Scholar
  • 4 Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009; 113 (15) 3406-3417
    CrossrefPubMedGoogle Scholar
  • 5 Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. First of two parts--blood transfusion. N Engl J Med 1999; 340 (06) 438-447
    CrossrefPubMedGoogle Scholar
  • 6 Muñoz M, García-Erce JA, Villar I, Thomas D. Blood conservation strategies in major orthopaedic surgery: efficacy, safety and European regulations. International Society of Blood Transfusion 2008; DOI: 10.1111/j.1423-0410.2008.01108.x.
    PubMedGoogle Scholar
  • 7 Goodnough LT, Maniatis A, Earnshaw P. , et al. Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. Br J Anaesth 2011; 106 (01) 13-22
    CrossrefPubMedGoogle Scholar
  • 8 Goodnough LT, Shander A. Patient blood management. Anesthesiology 2012; 116 (06) 1367-1376
    CrossrefPubMedGoogle Scholar
  • 9 Weber EW, Slappendel R, Hémon Y. , et al. Effects of epoetin alfa on blood transfusions and postoperative recovery in orthopaedic surgery: the European Epoetin Alfa Surgery Trial (EEST). Eur J Anaesthesiol 2005; 22 (04) 249-257
    CrossrefPubMedGoogle Scholar
  • 10 Slappendel R, Weber EW, Hémon YJ. , et al. Patients with and without rheumatoid arthritis benefit equally from preoperative epoetin-α treatment. Acta Orthop 2006; 77 (04) 677-683 (Level II)
    CrossrefPubMedGoogle Scholar
  • 11 Goldman M, Savard R, Long A, Gélinas S, Germain M. Declining value of preoperative autologous donation. Transfusion 2002; 42 (07) 819-823
    CrossrefPubMedGoogle Scholar
  • 12 Munoz M, Campos MA, Munoz E, Carrero A, Cuenca J, García-Erce JA. Red cell salvage in orthopedic surgery. Transfus Altern Transfus Med 2006
    PubMedGoogle Scholar
  • 13 Gillette BP, DeSimone LJ, Trousdale RT, Pagnano MW, Sierra RJ. Low risk of thromboembolic complications with tranexamic acid after primary total hip and knee arthroplasty. Clin Orthop Relat Res 2013; 471 (01) 150-154
    CrossrefPubMedGoogle Scholar
  • 14 Sirker A, Malik N, Bellamy M, Laffan MA. Acute myocardial infarction following tranexamic acid use in a low cardiovascular risk setting. Br J Haematol 2008; 141 (06) 907-908
    CrossrefPubMedGoogle Scholar
  • 15 Alshryda S, Sarda P, Sukeik M, Nargol A, Blenkinsopp J, Mason JM. Tranexamic acid in total knee replacement: a systematic review and meta-analysis. J Bone Joint Surg Br 2011; 93 (12) 1577-1585
    CrossrefPubMedGoogle Scholar
  • 16 Lassen MR, Ageno W, Borris LC. , et al; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358 (26) 2776-2786
    CrossrefPubMedGoogle Scholar
  • 17 Bierbaum BE, Callaghan JJ, Galante JO, Rubash HE, Tooms RE, Welch RB. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am 1999; 81 (01) 2-10
    CrossrefPubMedGoogle Scholar
  • 18 Baker P, Dowen D, McMurtry I. The effect of surgeon volume on the need for transfusion following primary unilateral hip and knee arthroplasty. Surgeon 2011; 9 (01) 13-17
    CrossrefPubMedGoogle Scholar
  • 19 Grover M, Talwalkar S, Casbard A. , et al. Silent myocardial ischaemia and haemoglobin concentration: a randomized controlled trial of transfusion strategy in lower limb arthroplasty. Vox Sang 2006; 90 (02) 105-112
    CrossrefPubMedGoogle Scholar
  • 20 Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 2012; 4 (04) CD002042
    PubMedGoogle Scholar
  • 21 Wright JG, Einhorn TA, Heckman JD. Grades of recommendation. J Bone Joint Surg Am 2005; 87 (09) 1909-1910
    CrossrefPubMedGoogle Scholar
  • 22 Spahn DR. Anemia and patient blood management in hip and knee surgery: a systematic review of the literature. Anesthesiology 2010; 113 (02) 482-495
    CrossrefPubMedGoogle Scholar
  • 23 Phan DL, Ani F, Schwarzkopf R. Cost analysis of tranexamic acid in anemic total joint arthroplasty patients. J Arthroplasty 2016; 31 (03) 579-582
    CrossrefPubMedGoogle Scholar
  • 24 García-Erce JA, Cuenca J, Muñoz M. Role of intravenous iron in elective and non-elective orthopedic surgery. Semin Hematol 2006; 34: S32-S35
    PubMedGoogle Scholar
  • 25 Feagan BG, Wong CJ, Kirkley A. , et al. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial. Ann Intern Med 2000; 133 (11) 845-854 (Level I)
    PubMedGoogle Scholar
  • 26 Karkouti K, McCluskey SA, Evans L, Mahomed N, Ghannam M, Davey R. Erythropoietin is an effective clinical modality for reducing RBC transfusion in joint surgery. Can J Anaesth 2005; 52 (04) 362-368 (Level III)
    CrossrefPubMedGoogle Scholar
  • 27 Jakovina Blazekovic S, Bicanic G, Hrabac P, Tripkovic B, Delimar D. Pre-operative autologous blood donation versus no blood donation in total knee arthroplasty: a prospective randomised trial. Int Orthop 2014; 38 (02) 341-346
    CrossrefPubMedGoogle Scholar
  • 28 Moonen AFCM, Thomassen BJW, Knoors NT, van Os JJ, Verburg AD, Pilot P. Pre-operative injections of epoetin-α versus post-operative retransfusion of autologous shed blood in total hip and knee replacement: a prospective randomised clinical trial. J Bone Joint Surg Br 2008; 90 (08) 1079-1083
    PubMedGoogle Scholar
  • 29 Salido JA, Marín LA, Gómez LA, Zorrilla P, Martínez C. Preoperative hemoglobin levels and the need for transfusion after prosthetic hip and knee surgery: analysis of predictive factors. J Bone Joint Surg Am 2002; 84-A (02) 216-220
    PubMedGoogle Scholar
  • 30 Muñoz Gómez M, García Vallejo J, López-Andrade Jurado A, Gómez Luque A, Ruiz Romero De La Cruz M, Maldonado Eloy-García J. [Autotransfusion after orthopedic surgery. Analysis of quality, safety and efficacy of salvaged shed blood] [Article in Spanish]. Rev Esp Anestesiol Reanim 2001; 48 (03) 131-140
    PubMedGoogle Scholar
  • 31 Carless P, Moxey A, O’Connell D, Henry D. Autologous transfusion techniques: a systematic review of their efficacy. Transfus Med 2004; 14 (02) 123-144
    CrossrefPubMedGoogle Scholar
  • 32 Rasouli MR, Maltenfort MG, Erkocak OF, Austin MS, Waters JH, Parvizi J. Blood management after total joint arthroplasty in the United States: 19-year trend analysis. Transfusion 2016; 56 (05) 1112-1120
    CrossrefPubMedGoogle Scholar
  • 33 Strümper D, Weber EW, Gielen-Wijffels S. et al. Clinical efficacy of postoperative autologous transfusion of filtered shed blood in hip and knee arthroplasty. Transfusion 2004; 44 (11) 1567-1571
    CrossrefPubMedGoogle Scholar
  • 34 Huët C, Salmi LR, Fergusson D, Koopman-van Gemert AW, Rubens F, Laupacis A. International Study of Perioperative Transfusion (ISPOT) Investigators. A meta-analysis of the effectiveness of cell salvage to minimize perioperative allogeneic blood transfusion in cardiac and orthopedic surgery. Anesth Analg 1999; 89 (04) 861-869
    CrossrefPubMedGoogle Scholar
  • 35 Whiting DR, Duncan CM, Sierra RJ, Smith HM. Tranexamic acid benefits total joint arthroplasty patients regardless of preoperative hemoglobin value. J Arthroplasty 2015; 30 (12) 2098-2101
    CrossrefPubMedGoogle Scholar
  • 36 Hourlier H, Fennema P. Tranexamic acid use and risk of thrombosis in regular users of antithrombotics undergoing primary total knee arthroplasty: a prospective cohort study. Blood Transfus 2018; 16 (01) 44-52
    PubMedGoogle Scholar
  • 37 Myles PS, Smith JA, Forbes A. , et al. Tranexamic acid in patients undergoing coronary-artery surgery. N Engl J Med 2017; 376 (02) 136-148
    CrossrefPubMedGoogle Scholar